ICON Partners with iCardiac Technologies to Provide an Earlier and More Precise Method for Evaluating Cardiac Safety

ICON Certified as a Partner of iCardiac’s Early Precision QT® Program

Dublin, Ireland, 3rd November, 2015 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that its clinical research unit in San Antonio is a certified and preferred site in iCardiac’s Early Precision QT Program. The certification enables ICON to offer iCardiac’s Early Precision QT® services for evaluating the cardiac safety of new compounds in Phase I clinical trials. This solution provides clients with an earlier and more precise assessment of the safety risk of their drug and potentially eliminates the need for a separate Thorough QT (TQT) study in later stages of development.

Read More

icon-logo_0ICON currently, operates from 77 locations in 38 countries and has approximately 11,700 employees. In Ireland, they employ over 1,000 staff from our global HQ in Dublin and from our office in Limerick.

Some highlights from quarter 3 include:

– An announcement with IBM, using the company’s Watson technology, that revolutionises patient recruitment in clinical trials
– A partnership with Mereo BioPharma, a specialty biopharma company, where ICON will be the sole provider of clinical development services to Mereo.
–  Nominated for the Best Technological Development in Clinical Trials by Scrip. Winners will be announced in December.

To read more, please click HERE.

aramarkIABCN Ambassador Club Member, ARAMARK, will continue its contract with The Guinness Storehouse for another five year term.

The food service company is planning to offer visitors new menu concepts that complement Ireland’s iconic draft beer.

The Storehouse, which began using Aramark in 2010, will also feature a new theatre style kitchen in Gilroy’s restaurant at the Dublin site, where tourists can watch chefs prepare their dishes.

The company, which has its headquarters in Center City, employs 270,000 people worldwide and roughly 7,500 people in the Philadelphia region.

To read more, please click HERE.

New €500,000 Enterprise Ireland fund aimed at overseas entrepreneurs and Irish diaspora

A new Enterprise Ireland fund will make up to €500,000 available to 10 overseas entrepreneurs and Irish diaspora who decide to set up their businesses in Ireland.

The fund will support start-up businesses in internationally focused manufacturing or internationally traded services.

Enterprise Ireland is inviting applications from individuals and early-stage companies of all nationalities. All applicants will have to agree to register as an Irish company before receiving investment from the agency. The majority of the management team/promoters must also agree to be based in Ireland for at least one year post investment.

To read more, please click HERE.

VPP_1742IABCN President, Kevin Kent, participated in a panel discussion on successful transatlantic partnerships.

Pioneering Transatlantic Business Partnerships

Chair: Frank Barry, Editor, Bloomberg View

Panel: Keith McKay, CFO Dalradian Resources, Toronto and Northern Ireland, Kevin Kent, President, Irish American Business Chamber and Network, Joanne Stuart, Director Northern Ireland Science Park Stevie Morrow, Partner Loughshore Investments, Belfast, and Options Technologies

Read More